Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the commencement of a Phase I clinical study for GLR1023, a biosimilar candidate to Novartis’ Cosentyx (secukinumab). The company has recently dosed the first patient in the trial, which is focused on evaluating the safety and efficacy of the anti-IL-17 antibody for the treatment of moderate-to-severe plaque psoriasis.
The originator product, Cosentyx, is already approved in China for the treatment of moderate to severe plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis. The market for similar products in China is competitive, with existing treatments including Eli Lilly’s Taltz (ixekizumab), Genrix Bio’s Jinlixi (xeligekimab), and Hengrui Medicine’s Andajing (vunakizumab).- Flcube.com
